A lack of stability in a specific region of the CFTR protein may explain why certain people with cystic…
Articles by Marisa Wexler, MS
Two experimental CFTR modulator therapies being developed by Sionna Therapeutics are able to improve the function of the most…
Treating expectant mothers with CFTR modulators may help to reduce the risk of intestinal complications for babies with…
Undergraduate and graduate students in the U.S. who have cystic fibrosis (CF) are invited to apply for…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to RCT2100, an experimental treatment for cystic…
The Cystic Fibrosis Foundation is once again accepting applications for its Impact Grants, a funding initiative that offers…
Biomx has raised $12 million in financing to advance BX004, a phage therapy being developed to treat bacterial infections…
A European Medicines Agency (EMA) committee recommended that the label for Kaftrio be expanded to cover treatment for people…
Boehringer Ingelheim has launched a Phase 1/2 clinical trial of BI 3720931, an inhaled gene therapy designed to treat…
Young children with cystic fibrosis (CF) have less mature gut bacterial growth over time than do their typically developing…